130 related articles for article (PubMed ID: 33194861)
1. Genetic Warfarin-Resistance Resulting in Surgery to Change a Prosthetic Valve.
Malik J; Ishaq U; Javed N; Baig MA; Javaid M
Eur J Case Rep Intern Med; 2020; 7(11):001851. PubMed ID: 33194861
[TBL] [Abstract][Full Text] [Related]
2. Warfarin dose requirements with different genotypes of CYP2C9 and VKORC1 for patients with atrial fibrillation and valve replacement.
Chen W; Wu L; Liu X; Shen Y; Liang Y; Zhu J; Tan H; Yang Y; Liu Q; Wang M; Liu L; Wang X
Int J Clin Pharmacol Ther; 2017 Feb; 55(2):126-132. PubMed ID: 27117036
[TBL] [Abstract][Full Text] [Related]
3. Genetic and clinical determinants influencing warfarin dosing in children with heart disease.
Nguyen N; Anley P; Yu MY; Zhang G; Thompson AA; Jennings LJ
Pediatr Cardiol; 2013 Apr; 34(4):984-90. PubMed ID: 23183958
[TBL] [Abstract][Full Text] [Related]
4. [Impact of CYP2C9 and VKORC1 polymorphism on warfarin response during initiation of therapy].
Liu Y; Zhong SL; Tan HH; Yang M; Fei HW; Yu XY; Lin SG
Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Oct; 39(10):929-35. PubMed ID: 22321278
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetics-Based Warfarin Dosing in Patients With Cardiac Valve Replacement: The Effects of CYP2C9 and VKORC1 Gene Polymorphisms.
Farzamikia N; Sakhinia E; Afrasiabirad A
Lab Med; 2017 Dec; 49(1):25-34. PubMed ID: 29182754
[TBL] [Abstract][Full Text] [Related]
6. Association of gene polymorphisms with the risk of warfarin bleeding complications at therapeutic INR in patients with mechanical cardiac valves.
An SH; Lee KE; Chang BC; Gwak HS
J Clin Pharm Ther; 2014 Jun; 39(3):314-8. PubMed ID: 24602049
[TBL] [Abstract][Full Text] [Related]
7. Effect of gene polymorphims on the warfarin treatment at initial stage.
Liu J; Jiang HH; Wu DK; Zhou YX; Ye HM; Li X; Luo ZY; Guo Z; Zhang YL; Wang YC; Zhang W; Zhou HH; Wang LS
Pharmacogenomics J; 2017 Jan; 17(1):47-52. PubMed ID: 26644206
[TBL] [Abstract][Full Text] [Related]
8. CYP2C9 Polymorphism and Unstable Anticoagulation with Warfarin in Patients Within the First 3 Months Following Heart Valve Replacement.
Wypasek E; Cieśla M; Suder B; Janik Ł; Sadowski J; Undas A
Adv Clin Exp Med; 2015; 24(4):607-14. PubMed ID: 26469104
[TBL] [Abstract][Full Text] [Related]
9. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population.
Ozer N; Cam N; Tangurek B; Ozer S; Uyarel H; Oz D; Guney MR; Ciloglu F
Heart Vessels; 2010 Mar; 25(2):155-62. PubMed ID: 20339978
[TBL] [Abstract][Full Text] [Related]
10. The influence of CYP2C9 and VKORC1 gene polymorphisms on optimal warfarin doses after heart valve replacement.
Tatarūnas V; Lesauskaitė V; Veikutienė A; Jakuška P; Benetis R
Medicina (Kaunas); 2011; 47(1):25-30. PubMed ID: 21681008
[TBL] [Abstract][Full Text] [Related]
11. Impact of genetic and clinical factors on warfarin therapy in patients early after heart valve replacement surgery.
Li B; Liu R; Wang C; Ren C; Zhang S; Zhang F; Zhang J; Liu S; Wei Y; Liu W; Song B; Wu X
Eur J Clin Pharmacol; 2019 Dec; 75(12):1685-1693. PubMed ID: 31444512
[TBL] [Abstract][Full Text] [Related]
12. Effect of CYP2C9 and VKORC1 genetic variations on warfarin dose requirements in Indian patients.
Natarajan S; Ponde CK; Rajani RM; Jijina F; Gursahani R; Dhairyawan PP; Ashavaid TF
Pharmacol Rep; 2013; 65(5):1375-82. PubMed ID: 24399734
[TBL] [Abstract][Full Text] [Related]
13. Validation of a proposed warfarin dosing algorithm based on the genetic make-up of Egyptian patients.
Ekladious SM; Issac MS; El-Atty Sharaf SA; Abou-Youssef HS
Mol Diagn Ther; 2013 Dec; 17(6):381-90. PubMed ID: 23839801
[TBL] [Abstract][Full Text] [Related]
14. The effect of CYP2C9, VKORC1 and CYP4F2 polymorphism and of clinical factors on warfarin dosage during initiation and long-term treatment after heart valve surgery.
Tatarunas V; Lesauskaite V; Veikutiene A; Grybauskas P; Jakuska P; Jankauskiene L; Bartuseviciute R; Benetis R
J Thromb Thrombolysis; 2014; 37(2):177-85. PubMed ID: 23677510
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetics of oral anticoagulants: a basis for dose individualization.
Stehle S; Kirchheiner J; Lazar A; Fuhr U
Clin Pharmacokinet; 2008; 47(9):565-94. PubMed ID: 18698879
[TBL] [Abstract][Full Text] [Related]
16. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
Shaw K; Amstutz U; Hildebrand C; Rassekh SR; Hosking M; Neville K; Leeder JS; Hayden MR; Ross CJ; Carleton BC
Pediatr Blood Cancer; 2014 Jun; 61(6):1055-62. PubMed ID: 24474498
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of genetic polymorphisms of CYP2C9 and VKORC1 - implications for warfarin management and outcome in Croatian patients with acute stroke.
Supe S; Božina N; Matijević V; Bazina A; Mišmaš A; Ljevak J; Alvir D; Habek M; Poljaković Z
J Neurol Sci; 2014 Aug; 343(1-2):30-5. PubMed ID: 24974237
[TBL] [Abstract][Full Text] [Related]
18. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients.
Miao L; Yang J; Huang C; Shen Z
Eur J Clin Pharmacol; 2007 Dec; 63(12):1135-41. PubMed ID: 17899045
[TBL] [Abstract][Full Text] [Related]
19. Influence of CYP2C9, VKORC1, and CYP4F2 polymorphisms on the pharmacodynamic parameters of warfarin: a cross-sectional study.
Sridharan K; Al Banna R; Malalla Z; Husain A; Sater M; Jassim G; Otoom S
Pharmacol Rep; 2021 Oct; 73(5):1405-1417. PubMed ID: 33811620
[TBL] [Abstract][Full Text] [Related]
20. Impact of CYP2C9, VKORC1 and CYP4F2 genetic polymorphisms on maintenance warfarin dosage in Han-Chinese patients: A systematic review and meta-analysis.
Zhang J; Chen Z; Chen C
Meta Gene; 2016 Sep; 9():197-209. PubMed ID: 27617219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
